Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions: Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Obesity Hypoventilation Syndrome, Ketogenic Dieting, Hypercapnic Respiratory Failure
Interventions: Ketogenic Diet; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anesthesia, Local, Pain
Interventions: 1% Buffered Lidocaine 1:100,000 Epinephrine, 2% Unbuffered Lidocaine 1:100,000 Epinephrine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 12 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tobacco Use Disorder
Interventions: Camel Snus, Marlboro Snus, Stonewall, Ariva, General Snus; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Eugene, Oregon

Conditions: Healthy
Interventions: JNJ-54416076 (Oral Suspension), JNJ-54416076 (Formulation 1: Direct Compression Tablets), JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stroke Hemorrhagic, Depression
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Lidocaine topical system 1.8%; Drug
Lead sponsor: Scilex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 506
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Esophageal Cancer
Interventions: Erlotinib, Bevacizumab, Paclitaxel, Carboplatin, 5-FU, Radiation therapy, Surgery; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 9
States / cities: Fort Myers, Florida • Jacksonville, Florida • Gainesville, Georgia + 6 more

Conditions: Type 1 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Reiki therapy; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more

Conditions: Prostate Cancer
Interventions: zoledronate therapy, PET Scan; Drug · Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Farmington Hills, Michigan

Conditions: Mental Stress, Emotional Stress
Interventions: TICM, TICO; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Childhood Obesity Prevention
Interventions: digital intervention + home visiting curriculum, Home visiting curriculum; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 16 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Generalized Myasthenia Gravis
Interventions: ALXN1830, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Frailty
Interventions: Meals plus exercise, Meals only; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ankyloglossia, Impairment of Speech, Slurred Speech
Interventions: P1821; Device
Lead sponsor: Dream Video LLC; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions: Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor; Behavioral · Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 86
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Search by objective public record fields.

FirstStep2Health Intervention

Ketogenic Diet for Obesity Hypoventilation Syndrome

Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years

Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Poststroke Depression in Hemorrhagic Stroke

Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Trauma Informed Care for Newly Resettled Refugees

Digitally Delivered Child Obesity Prevention for Parents in Home Visiting Programs

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Meal Delivery and Exercise

Effectivity of P1821, a Novel Tongue Strengthening and Endurance Enhancing Speech Flow Exercise

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication